Recent 8-K filings for OTLC
Highest-materiality recent filing
Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain
- Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.
- Non-cash gain of $365.4M from fair value increase in GMP Bio JV investment, partially offset by $111.6M deferred tax provision.
-
Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock
Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).
-
Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain
Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.
-
Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform
Joint development, manufacturing, and licensing agreement signed March 31, 2026.
-
Oncotelic raises $358.5K via secured convertible note with Mast Hill Fund
Issued $398,333.33 convertible promissory note (10% OID, 10% interest, 1-year maturity) to Mast Hill Fund for net proceeds of ~$350K after fees.
-
CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.
-
Oncotelic completes Tranche 3 of unit offering, raising $1.1M from 22 investors
Issued 44 units under final Tranche 3; each unit includes a $25,000 principal, 12% 2-year convertible note.
-
Oncotelic closes initial $800K convertible note offering at 12% with warrants
Issued 32 units at $25,000 each to 21 accredited investors; total $800,000 raised.
-
Oncotelic closes initial 11 units of up to 500-unit offering with 12% notes and warrants
Initial closing of 11 units at $25,000 each in best-efforts offering of up to 500 units.
-
Engaged Jefferson Capital Ventures and Valor Nation for 18-month consulting and advisory services starting August 6, 2025.
-
Oncotelic secures $560K convertible note from Mast Hill; enters $25M equity purchase agreement
Issued $560,000 convertible promissory note to Mast Hill Fund, 10% OID, 10% interest, convertible at $0.07/share.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material